secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001558370-24-008779
Event type: other
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path presents positive interim Phase 2 prexigebersen AML data at ASCO and EHA
--------------------------------------------------------------------------------

- ASCO oral presentation on June 1, 2024 (8:00 AM CT, McCormick Place, abstract #6511).
- EHA poster presentation on June 14, 2024 (6:00 PM CEST, Madrid, abstract #P536).
- Interim Phase 2 data for prexigebersen (BP1001) plus decitabine/venetoclax in AML show it's well-tolerated with compelling efficacy.
- Data from newly diagnosed and refractory/relapsed cohorts both exceeded outcomes with frontline therapy.
- No specific numerical results were disclosed in the press releases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024008779/0001558370-24-008779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024008779/bpth-20240523x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer